COR111096, A Randomized, Double-Blind, Active-Controlled, Parallel Group, Multicenter Study Comparing The Proportion of Subjects With Stage 1 or 2 Essential Hypertension Who Achieve Target Blood Pressure While Receiving Either COREG CR [carvedilol] + Lisinopril or Lisinopril Monotherapy

Trial Profile

COR111096, A Randomized, Double-Blind, Active-Controlled, Parallel Group, Multicenter Study Comparing The Proportion of Subjects With Stage 1 or 2 Essential Hypertension Who Achieve Target Blood Pressure While Receiving Either COREG CR [carvedilol] + Lisinopril or Lisinopril Monotherapy

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Jun 2015

At a glance

  • Drugs Carvedilol (Primary) ; Lisinopril
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 04 Sep 2009 Actual patient numbers amended from (432) to (348) as reported by ClinicalTrials.gov.
    • 04 Sep 2009 Actual end date (Mar 2008) added as reported by ClinicalTrials.gov.
    • 05 Aug 2009 Actual patient number (432) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top